

STATUS OF THE CLAIMS

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

Claims 1, 9, 11-13 and 38-41 are examined in the present office action.

1. (Previously Presented) A reaction mixture, comprising:

- a) a first oligonucleotide primer comprising i) a T7 promoter sequence, ii) a ribosome binding site sequence, iii) a start codon, iv) a sequence coding for a first epitope marker, v) a sequence coding for a second epitope marker, wherein said first and second epitope markers are different, and vi) a first region of complementarity to a region of a gene of interest; and
- b) a second oligonucleotide primer comprising i) at least one stop codon, and ii) a sequence encoding for a third epitope marker, wherein said third epitope marker is different from said first and second epitope markers and wherein said first and third epitope markers are selected from the group consisting of SEQ ID NOS: 5, 6, 7, 8 and 9.

2-8. (Canceled)

9. (Previously Presented) A kit, comprising:

- a) a first oligonucleotide primer comprising i) a T7 promoter sequence, ii) a ribosome binding site sequence, iii) a start codon, iv) a sequence coding for a first epitope marker, v) a sequence coding for a second epitope marker, wherein said first and second epitope markers are different, and vi) a first region of complementarity to a region of the APC gene;
- b) a second oligonucleotide primer comprising i) at least one stop codon, and ii) a sequence coding for a third epitope marker, wherein said third epitope marker is different from said first and second epitope markers and wherein said first and third epitope markers are selected from the group consisting of SEQ ID NOS: 5, 6, 7, 8 and 9;
- c) a microtiter plate coated with a ligand capable of binding to said second epitope marker;

- d) a first antibody capable of binding to said first epitope marker; and
- e) a second antibody capable of binding to said third epitope marker.

10. (Canceled)

11. (Previously Presented) The kit of Claim 9, wherein said second oligonucleotide primer further comprises iii) a second region of complementarity to a region of the APC gene.

12. (Previously Presented) The kit of Claim 9, wherein said first region of complementarity is greater than 15 bases in length.

13. (Previously Presented) The kit of Claim 11, wherein said second region of complementarity is greater than 15 bases in length.

14-37. (Canceled)

38. (Previously Presented) The reaction mixture of Claim 1, wherein said first and second epitope markers are 3' of said start codon.

39. (Previously Presented) The reaction mixture of Claim 1, wherein said sequence coding for a third epitope marker is the reverse complement sequence of said epitope marker.

40. (Previously Presented) The reaction mixture of Claim 1, wherein said third epitope marker is 5' of said stop codon.

41. (Previously Presented) The kit of Claim 9, wherein said first and second epitope markers are 3' of said start codon.